Germ line insertion of a human endogenous retroviruslike element (HERV-E.PTN) into the growth factor pleiotrophin (PTN) gene generated a phylogenetically new promoter driving the expression of functional HERV-PTN fusion transcripts. Here we show by in situ hybridization, that HERV-PTN fusion transcripts are expressed in malignant trophoblasts (i.e. choriocarcinoma) and in the proliferative and in the invasive trophoblasts of gestational trophoblastic tissue. Additionally, a 1.9 kb fragment of the HERV-derived PTN promoter was analysed which has strong activity when transiently transfected into choriocarcinoma JEG-3 cells in contrast to HeLa cells. Deletion of the retrovirallyderived promoter portion abolished its activity and an enhancer (+443 to +486) was identi®ed in this region. Electrophoretic mobility shift and supershift experiments identi®ed a Sp1 binding site in this enhancer and site speci®c mutation of this site abolished its activity in choriocarcinoma cells. Sp1 overexpression in Drosophila SL2 cells showed that the enhancer activity is mediated via Sp1 binding in vivo. Furthermore, mutation of the Sp1 binding site reduced the activity of a promoter test fragment in choriocarcinoma cells by 80%. Our result shows that a retroviral Sp1 binding site in the PTN promoter is important for the expression of growth factor pleiotrophin in human choriocarcinoma cells.
Introduction
Pleiotrophin (PTN), is a secreted protein that belongs to a new family of highly conserved heparin-binding growth factors. PTN was originally described as a developmentally-regulated cytokine with neurite outgrowth activity and later shown to play a role in human tumors (for review see, Schulte and Wellstein, 1997) . In contrast to its limited expression in adult tissues (Bloch et al., 1992; Vanderwinden et al., 1992) , PTN is upregulated in human cancer cell lines and tumor specimens of dierent origin Fang et al., 1992; Vacherot et al., 1999) . Beside its neurite-outgrowth activity (Boehlen et al., 1991) , PTN has mitogenic and transforming activity on ®broblasts (Chauhan et al., 1993; Fang et al., 1992) , growth promoting activity on epithelial and endothelial cells (Courty et al., 1991; Fang et al., 1992) and induces tube formation of endothelial cells in vitro and angiogenesis (Laaroubi et al., 1994; Choudhuri et al., 1997) . Furthermore, PTN enhances plasminogen activator activity in endothelial cells (Boyd et al., 1993) and seems to play an essential role for the growth of models of human breast cancer , choriocarcinoma and for the growth, angiogenesis and metastasis of human melanoma .
We recently de®ned the organization of the human PTN gene and identi®ed a novel human endogenous retrovirus-like element (HERV-E.PTN) inserted into the intron region immediately upstream of the ®rst coding exon. This insertion expands the region relative to the murine gene and phylogenetic studies suggest that its insertion into the PTN locus happened approximately 25 million years ago Schulte and Wellstein, 1998) . Furthermore, a genomic fragment containing the retroviral insertion site showed strong transcriptional activity in trophoblast-derived choriocarcinoma cells. Due to this phylogenetically novel promoter, fusion transcripts between HERV-E.PTN sequence and the open reading frame of PTN are expressed in normal trophoblast cells and in choriocarcinoma cell lines .
HERV elements are assumed to be prehistoric sequences from infective retroviruses which inserted into the germ-line of human progenitors millions of years ago (for reviews see Wilkinson et al., 1994; Loewer et al., 1996; Patience et al., 1997; Harris, 1998) . Retroviral transcripts have been detected in dierent human tissues and cell lines, preferentially of placental, embryonic or neoplastic origin (Rabson et al., 1983; Gattoni-Celli et al., 1986; Herbst et al., 1996; Johansen et al., 1989) , and some investigators reported the identi®cation of HERV fusion transcripts with endogenous genes (DiCristofano et al., 1995; FeuchterMurthy et al., 1993; Liu and Abraham, 1991) . However, to our knowledge, only two reports of a HERV germ-line insertion that generated changes in the expression pattern of a functional human gene product have been published to date: the phylogenetically novel expression of human amylase in salivary gland (Samuelson et al., 1990; Ting et al., 1992) , and the expression of the growth factor PTN in human trophoblasts and in choriocarcinoma cell lines Schulte and Wellstein, 1998) .
To shed light on the function and transcriptional regulation of human growth factor PTN expression in the trophoblast we now report the cellular distribution of HERV-PTN fusion transcript expression in normal and malignant trophoblast tissues and provide an analysis of the HERV-derived PTN gene promoter. In situ hybridization experiments showed HERV-PTN mRNA expression in the proliferative and invasive trophoblasts of gestational trophoblast tissue and in choriocarcinoma specimens. Promoter deletion analysis demonstrated a crucial role for the retroviral part of the promoter and revealed the presence of a retroviral enhancer. By protein/DNA binding studies and supershift experiments we de®ned a Sp1 binding site in this enhancer region. Sp1 overexpression in Drosophila SL2 cells con®rmed the essential role of Sp1 for the activity of the retroviral enhancer. Mutation of this site diminished the enhancer activity in choriocarcinoma cells and reduced most of the activity of a promoter fragment (80%).
Results

Cellular distribution of HERV-PTN fusion transcript expression in normal and malignant human trophoblastic tissue
To elucidate the potential role of growth factor PTN in normal and malignant human trophoblastic tissues, we studied the cellular expression of HERV-PTN mRNA in term placenta, in pathologic placenta from the second trimester (complete mole) and in choriocarcinoma tissue by in situ hybridization. Ribprobes, speci®c for the PTN coding region and the HERVderived 5' untranslated exon UV3 of the HERV-PTN mRNA were used in parallel (Figure 1a,b) . In term placenta tissue, both antisense probes revealed strong stainings in the intermediate trophoblast, a subpopulation of the cytotrophoblast which invades the myometrium at the implantation site ( Figure 1c , III to VI). Keratin staining was used to highlight the intermediate trophoblast and distinguish it from the decidua ( Figure  1c , II). Due to the small fraction of cytotrophoblast in term placenta, we used hydatidiform complete mole tissue to further assess the PTN expression status in this cell type. Complete mole tissue is characterized by chorionic villus formation, trophoblastic proliferation and lack of embryoblast cells (Silverberg and Kurman, 1992) . Both antisense riboprobes stained the cytotrophoblast (Figure 1d ). In choriocarcinoma tissue a strong staining was obtained in the malignant trophoblasts with both antisense probes (Figure 1e ). We conclude from this that PTN is expressed in malignant and in normal proliferative and invasive trophoblasts.
Influence of the retroviral sequence on the human PTN gene promoter activity
We showed earlier that a 1.9 kb genomic fragment (71266 to +631) containing 629 nt HERV-E.PTNderived sequence (+3 to +631) confers strong transcriptional activity when transiently transfected into choriocarcinoma cells . To assess the retroviral contribution to this activity, we analysed serial promoter deletion constructs in JEG-3 choriocarcinoma cells that express HERV-PTN fusion transcript in comparison to PTN negative HeLa cells (Figure 2a,b) .
In JEG-3 cells, comparable strong transcriptional activities were obtained for the 5' deletion mutants 7729/+631, 7601/+631 and 7353/+631 as seen for the 1.9 kb promoter fragment (71266/+631) ( Figure  2b ). In contrast, 3' deletions in the 5' LTR of the retroviral element showed a dramatic reduction in transcriptional activity. Deletion of the retroviral fragment +404 to +631, containing the U5, R and the 3' end of the U3 region (Schulte and Wellstein, 1998) , reduced the promoter activity 34-fold and 3' deletion up to position +32 abolished the transcriptional activity in JEG-3 cells (construct 7601/+32, Figure 2b ). These data indicate that the retroviral sequence +404 to +631 contains the major regulatory elements responsible for the strong activity of promoter fragment 71266 to +631 in JEG-3 cells. When tested in HeLa cells, almost only background activity was obtained for the entire promoter and for the deletion constructs ( Figure 2b ).
The HERV-derived sequence from position +404 to +631 showed transcriptional activity in either orientation in JEG-3 cells when placed directly upstream of the reporter gene ( Figure 2c ). The reporter vector showed no activity by itself (Figure 2b ). However, region +404 to +631 is about threefold more active in its positive versus its negative orientation. Mutation of the 5' untranslated exon UV3 splice donor at position +533/+534 (SDmt) did not aect these activities (Figure 2c ). These data suggest that the activity seen in both orientations could be due to an enhancer element(s) contained in region +404 to +631. However, activated transcription from the exonic HERV-derived region +404 to +631 must be initiated by a transcription start site which is dierent from the transcription start site of the HERV-PTN mRNA . Presumably, spontaneous start sites in the reporter vector backbone are utilized.
Transcriptional activity of promoter region +404/+631
To characterize the bidirectional transcriptional activity of region +404 to +631, subfragments (+404/ +486 and +486/+631) were tested in either orientation upstream of the reporter gene. Interestingly, independent of the orientation, region +404 to +486 has similar activity as fragment +404 to +631 in negative orientation (Figure 3a) . In contrast, region +486 to +631 shows only background activity in either orientation. These results suggest that an orientation-independent activating element is located between position +404 to +486. We next asked whether this region would act as an enhancer upstream of a heterologous promoter. To test this, region +404 to +486 was cloned in either orientation upstream of the CMV minimal promoter (CMVmi; 753 to +75) ( Figure 3b ). Independent of its orientation, region +404 to +486 mediates an approximate eightfold increase in the activity of the CMVmi promoter in JEG-3 cells and similar eects were also seen in the choriocarcinoma cell lines BeWo (12-fold) and JAR (3.5-fold) (data not shown). Additionally, subfragments of this enhancer region revealed equivalent activity in JEG-3 cells for region +443 to +486 than seen for the UT-exon U1 to coding exon O1) and for the 5'UTR of the HERV-PTN fusion transcript (C=5'UT-exon UV3 to coding exon O1) were used in the RT ± PCR experiments. The hybridization was performed with nested primers from coding exon O1 and O2 in parallel. To control for the quality of each cDNA, a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) speci®c RT ± PCR was performed (1=JAR, 2=BeWo, 3=JEG-3, 4=HeLa; lower panel). (b) Localization of the 1.9 kb promoter fragment and its transcriptional activity. The promoter fragment is enlarged and sequence positions are given relative to the transcription start site of the HERV-PTN fusion transcripts (=+1). Transcriptional activity of region 71266 to +631 and various 5'-and 3'-truncated fragments inserted into the promoterless pXP-1 ®re¯y luciferase (F.Luc) reporter vector are shown. (c) Region +404 to +631 has transcriptional activity in JEG-3 cells in either orientation and is independent of the UV3 splice donor. Transcriptional activity of the wild-type fragment +404 to +631 and the UV3 splice donor mutated fragment (+404/+631 SDmt) were inserted in either orientation in the reporter vector pXP-1 as indicated. The orientation of each construct is shown. These data are the mean+s.e.mean of at least three independent experiments with triplicate samples. The activities are shown after normalization for transfection eciency (CMV-LUC) and protein content. Several constructs were also tested in cotransfection experiments with CMV-driven chloramphenicol acetyltransferase expression vector (CMV-CAT, 15 ng) and the results obtained after CAT normalization or after normalization to the transfection eciency control CMV-LUC were virtually identical region +404 to +486. However, no activity was obtained when these enhancer constructs were transfected into HeLa cells (Figure 3b ). Taken together, these data show that a retroviral enhancer with activity in choriocarcinoma cells is located between position +443 to +486. To examine any trans-acting factors bound to this region, electrophoretic mobility shift assays (EMSAs) were performed.
Analysis of protein binding to region +443 to +490
EMSAs were performed with endlabeled doublestranded oligonucleotide +443 to +490 and extracts from JEG-3 and HeLa cells (Figure 4a ,b). Four protein-DNA complexes (Figure 4b ) of dierent mobility and intensity were detected with both cell extracts. However, competition with unrelated DNA (UC1, see Figure 4b ) revealed DNA binding speci®city for only one protein-DNA complex which we named complex 1 (lane 7 in Figure 4b ). The other three complexes were considered by us as nonspeci®c (NS; Figure 4b ). To identify the binding site of complex 1, three overlapping oligonucleotides encompassing the region +443 to +490 were used as competitors (Figure 4c ). Only oligonucleotide +443/+465 competed for protein-DNA complex 1 suggesting its binding site within this region. Indeed, protein-DNA complex 1 was obtained when using oligonucleotide +443/+465 as the probe (Figure 4c) . Interestingly, consensus analysis revealed a potential retrovirallyderived Sp1 binding site in this region. Position +453 to +462 (5'-GCCACTCCCT-3') is similar to the Sp1 binding site I (755 to 746; 5'-GCCACTCCCC-3') originally found in the upstream promoter of the human immunode®ciency virus-1 (HIV-1) with only one nucleotide aberration (underlined; Jones et al., 1986) . Furthermore, a Sp1 binding site consensus oligonucleotide successfully competed with complex 1 (Figure 4a ; data not shown) and complex 1 was speci®cally supershifted by an anti-Sp1 antibody (Figure 4d ). Competition experiments with various mutants mapped the Sp1 binding site to position +451/+462 (data not shown). Taken together our data show that Sp1 is capable of binding in vitro to the enhancer region.
Role of the Sp1-binding site for the enhancer activity of region +443 to +490
To test the signi®cance of the Sp1-binding site on the activity of the enhancer, we mutated the site at position +459/+460 (+443/+490mt.Sp1) in the enhancer fragment +443/+490 (Figure 5a ). EMSA with JEG-3 extract con®rmed a loss of Sp1-binding with this mutation (Figure 4e ). Transfection experiments ( Figure  5b) show that the Sp1-binding site is essential for the Figure 3 Analysis of retroviral-derived promoter region +404/+486. (a) Region +404 to +486 and +486 to +631 were inserted in either orientation into the pXP-1 reporter vector and compared with the transcriptional activity of construct +631 to +404 into JEG-3 cells. (b) Region +404 to +486 and the subfragments +443 to +404 and +443 to +486 were inserted in dierent orientations upstream of the CMVminimal promoter (CMVmi; 753 to +75) cloned into the pXP-1 reporter vector and transiently transfected in JEG-3 and HeLa cells. The activities are expressed relative to that obtained with the CMVmi promoter alone. Cells were transiently transfected with circular plasmid DNA (1 mg) as described in Materials and methods and the data are the mean+s.e.mean of at least three independent experiments with triplicate samples. The results obtained after normalization to CAT, R.LUC or to the transfection eciency control CMV-LUC were virtually identical (Figure 4d ), the wildtype enhancer construct and the Sp1 binding site mutant showed no dierent activities (Figure 5b) . Therefore, we speculate that an interaction of Sp1 with other DNA-or non-DNA binding factors could be responsible for the enhancer activity seen in choriocarcinoma cells.
Sp1 binding activates the enhancer in vivo
To elucidate whether enhancer region +443 to +486 can be activated by the Sp transcription factor family member Sp1 in vivo, the Drosophila SL2 cell line was utilized. SL2 cells lack Sp1-like activity and have been used by others before to directly assess the transcriptional role of Sp1 (e.g. Courey and Tjian, 1988) . In detail, a reporter construct containing region +443/ +486 upstream of the CMVmi promoter was cotransfected into SL2 cells with an expression vector for Sp1 (pPACSp1). The DNA-binding site speci®city of Sp1 protein expressed in SL2 cells was indistinguishable from endogenous Sp1 in JEG-3 cells (Figure 6a ). The transfection experiments show that Sp1 can activate enhancer region +443/+486 in vivo ( Figure  6b) .
Role of the Sp1-binding site +451 to +462 on the promoter activity of region 7601 to +631
To de®ne the role of the retroviral Sp1-binding site on the promoter activity, the adenine mutant +459/+460 was inserted into promoter fragment 7601 to +631. An overall ®vefold decrease in transcriptional activity was obtained for the Sp1-mutant promoter fragment when tested in JEG-3 (Figure 7 ) or BeWo and JAR cells (data not shown). The promoter background activity in HeLa cells was reduced approximately threefold by the Sp1 mutation (data not shown). These data indicate that 80% of the promoter activity of the PTN gene in choriocarcinoma cells is due to the Sp1 binding site at position +451 to +462 provided by the retroviral insertion.
Discussion
Various placenta types have been developed in mammals to ensure the proper exchange of molecules between the fetal and maternal blood (Leisner and Kaufmann, 1994) and the human hemochorial placenta is considered the most invasive one. Human intermediate trophoblast cross the uterine epithelium, invade the decidua, the inner third of the myometrium and the maternal arteries (Graham and Lala, 1992) . This extensive intermingling of trophoblast with maternal cells as seen in human is dierent for example in the mouse hemochorial placenta in which trophoblast and maternal cells are rather demarcated from each other (Graham and Lala, 1992) . Indeed, human trophoblasts have similar abilities as tumor cells in as much as they are both capable of penetrating the basement membrane and invading maternal blood vessels (Zhou et al., 1997) . Interestingly, earlier work from our laboratory showed that human primary trophoblast cell cultures and human placenta tissues express the growth factor pleiotrophin (PTN) as do human trophoblast-derived choriocarcinoma cells. This phylogenetically novel expression pattern of PTN is due to the insertion of an endogenous retrovirus-like element (HERV-E.PTN) in the human PTN gene . Furthermore, similar to its role in breast cancer and melanoma , our earlier work also suggests that PTN could be rate limiting for the growth of human choriocarcinoma . To further elucidate the role of PTN in human trophoblastic tissue we performed in situ hybridization experiments. Beside the detection of PTN in malignant trophoblasts, we detected PTN expression in proliferative (cytotrophoblast) and invasive (intermediate) normal human trophoblasts. This supports our hypothesis that PTN could contribute also to the aggressive growth phenotype of normal human placenta.
To understand the transcriptional regulation of HERV-PTN fusion transcript expression in human trophoblastic cells, we analysed the promoter of the human PTN gene. In particular, a 1.9 kb promoter fragment (71266 to +631) containing 629 nt retroviral sequence (+3 to +631) was mapped to assess the retroviral contribution to its transcriptional activity. Transfection experiments showed strong activity of this promoter fragment in choriocarcinoma cells and only background activity when tested in PTN negative HeLa cervical carcinoma cells. Deletion analysis revealed an essential role of the retrovirusderived sequence (+3 to +631) for the promoter activity. Furthermore, we de®ne an enhancer (pos. +443 to +486) which is speci®cally active in choriocarcinoma cells but not in HeLa cells. The enhancer is located in the 5' LTR of the HERV-E.PTN element and contains a Sp1 binding site (+451 to +462). Although no cell-type speci®c Sp1 binding in vitro was observed, functional analysis revealed that the Sp1-site is essential for the enhancer activity in choriocarcinoma cells and Sp1 overexpression in Drosophila SL2 cells showed that Sp1 is mediating its activity in vivo (pos. +451 to +462). Consequently, the cell-type-speci®c activity pattern of the enhancer can not be explained by Sp1 itself. Interestingly, preliminary experiments from our laboratory indicate that the activity of the enhancer in choriocarcinoma cells is mediated by interaction of Sp1 with other trans-acting factor(s) (unpublished data). Furthermore, our data show that the Sp1-site is responsible for *80% of the transcriptional activity of the HERV-derived PTN promoter.
Sp1 is an ubiquitously expressed, zinc ®nger protein involved in the expression of various cellular and viral genes via binding to a classical GC box (GGGCGGG) or to related motifs. Sp1 binding sites can be located distal and/or proximal to the transcription start site of genes and are shown to be critical for basal promoter and/or enhancer activities (for review see Suske, 1999; Nuchprayoon et al., 1999) . Furthermore, Sp1 can also interact with other proteins such as OTF-1 (Janson and Petterson, 1990) , BPV enhancer E2 protein (Li et al., 1991) , YY1 (Seto et al., 1993) , NF-kB (Perkins et al., 1993) , GATA-1 (Merika and Orkin, 1995), Rb (Ubvadia et Figure 7 Mutation of the Sp1-binding site +451/+462 decreases the transcriptional activity of promoter fragment 7 601 to +631 in choriocarcinoma cells by 80%. JEG-3 cells were transfected with dierent promoter-reporter constructs (1 mg) as described in Materials and methods. The activities are shown after normalization with the transfection eciency control R.LUC al., 1995), E2F-1 (Lin et al., 1996) to contribute to tissue-speci®c gene regulation.
In summary, we show that HERV-PTN fusion transcripts are expressed in the malignant trophoblasts of choriocarcinoma and in the proliferative and invasive trophoblasts of gestational trophoblastic tissue. Additionally, the retroviral sequence part of the PTN promoter was de®ned as being crucial for its strong transcriptional activity in choriocarcinoma cells and a Sp1 binding site was de®ned in this region. Furthermore, mutation of this Sp1 binding site reduced the activity of a promoter test fragment in choriocarcinoma cells by 80%.
Materials and methods
Cell lines, transient transfection experiments, firefly-luciferase, renilla-luciferase and chloramphenicol acetyltransferase (CAT) assay
Human choriocarcinoma (JEG-3, JAR, BeWo) and cervical carcinoma (HeLa) cells as well as Schneider's Drosophila cell line 2 (SL2) were obtained from American Type Culture Collection. The human cells were grown in improved minimal essential medium (IMEM) with 10% fetal bovine serum at 378C with 5% CO 2 , the non adherent insect cell line was cultured in Schneider's Drosophila medium with 10% fetal bovine serum (Life Technologies, Gaithersburg, MD, USA) at 258C without CO 2 . All human cells were transiently transfected with various ®re¯y luciferase-reporter gene constructs and a cytomegalovirus promoter (CMV)-driven ®re¯y luciferase (F.Luc) expression vector in 6-well plates with 1 mg circular plasmid DNA per well using 7 ml LipofectAmine (Life Technologies, Gaithersburg, MD, USA) as described earlier . In cotransfection experiments 36 ng CMV-driven chloramphenicol acetyltransferase (CAT) or 2.5 ng CMV-driven renilla luciferase (R.Luc) expression vectors (pRL-CMV, Promega, Madison, WI, USA) were added to control for transfection ecacy. Drosophila SL2 cells were transfected with a calcium phosphate transfection system (Life Technologies) in 6-well plates containing one million cells per well as described by the vendor. In detail, every well received 4 mg of circular plasmid DNA including 10 ng of renilla luciferase expression vector (pPACR.Luc) as an internal standard for transfection eciency. Dierent amounts of Sp1 expression vector pPACSp1 (Courey and Tjian, 1988) were added to 1 mg of the promoter-reporter construct and compensated with the empty expression vector pPAC (Courey and Tjian, 1988) . About 22 h after addition of DNA, 4 ml growth medium was added to each well and 24 h later the cells were harvested, washed with 16PBS and lysed in 150 ml lysis buer from the dual-luciferase assay system (Promega). In all transient transfection experiments each construct was tested in triplicate and the experiments were repeated at least three times. The luciferase activities were determined using the ®re¯y luciferase or the dual-luciferase assay system as recommended by the vendor (Promega). The protein content of cell lysate was determined using the Bio-Rad protein detection system (Hercules, CA, USA) (Bradford, 1976) . To assay for CAT activity, the cells were harvested with trypsin and 60% of them were lysed in 30 ml 0.1 M Tris-HCl pH 7.8 by three freeze-thaw cycles. The CAT-assay was done as described by Neumann et al. (1987) . Brie¯y, 3 mg of protein in 50 ml 0.1 M Tris-HCl pH 7.8 were added to 200 ml reaction buer (1.25 mM chloramphenicol, 0.1 M Tris-HCl pH 7.8, 0.125 mM acetyl CoA, 35.25 pmol 3 H-acetyl CoA (0.1 mCi/ ml, DuPont NEN, Boston, MA, USA)), overlaid with 2 ml of scintillation¯uid (Econo¯uor-2, DuPont), incubated for 30 min and measured.
Reverse transcriptase (RT)-PCR PCR and generation of digoxigenin (DIG)-UTP labeled riboprobes
Avian myeloblastosis virus (AMV) reverse transcriptase and random primers (p(dN) 6 ) (Boehringer Mannheim, Indianapolis, IN, USA) were used to generate cDNA from 1 mg of total RNA. Thirty cycle PCR reactions (45 s at 958C, 45 s at 38C below the predicted melting point of the respective oligonucleotide and 45 s at 728C) with various primer combinations (PTN primer O2, 5'-AGTCTGACTGTGGA-GAAT GG-3' with O4, 5'-ATGTTCCACAGGTGACATC-3'; PTN primer, U1, 5'-GTCAGGGCGTAATTGAGTC-3' or UV3, 5'-CCTGACTTGCTCAGTCGATC-3' with primer O1, 5'-CACTATCCACAGCTGCCAG-3'; GAPDH primer I 5'-AAGGTGAAGGTCGGAGTCAACG-3' and II 5'-TGGTGGTGCAGGATGCATTGCT-3' to test the cDNA quality; two PTN UV3 primers 5'-GGACAAGAGAGACC CTCTC-3', 5'-GACGAGCCGCGGACAG G-3' to isolate the exon UV3 cDNA; two renilla luciferase cDNA adapter primers 5'-GCAGGATCCATGACTTCGAAAGTTTATGATCC-3', 5'-GCACTCGAGCATGTCTGCTCGAAGCGGC-3' to isolate the renilla cDNA from the renilla expression vector pRL-CMV) were performed with recombinant Taq polymerase from Life Technologies as recommended by the vendor. The exon UV3 cDNA (485 nt) was ligated into the PCR vector pCR2.1 (Invitrogen, Carlsbad, CA, USA), the renilla cDNA (963 nt) was ligated into the pPAC drosophila expression vector (Courey and Tjian, 1988) via BamHI/XhoI. The PTN open reading frame cDNA clone (pRC/PTN) was described earlier .
To generate the antisense and sense riboprobes from the exon UV3 and the PTN ORF (ORF antisense (551 nt) and sense (551 nt), UV3 antisense (362 ng) and sense (485 nt)), the clones pCR/UV3 and pRC/PTN were linearized with BglII or NotI and HindIII or XbaI, respectively. The DIG-UTP RNA labeling was performed with the labeling mix from Boehringer Mannheim as recommended by the vendor and tested on DNA dot blots.
In situ hybridization and immunohistochemistry
The experiments were performed according to PanoskaltsisMortari and Bucy (1995) with small modi®cations. Deparanized sections of formalin-®xed tissues were treated for 15 min with proteinase K (10 mg/ml, Sigma) at room temperature and washed with 26SSC prior to acetylation. Hybridization solution (100 ml/slide; 50% formamide, 46SSC, 16Denhardt's solution, 5 mg/ml heat denatured salmon sperm DNA, 2.5 mg/ml yeast tRNA, 10% dextran sulfate) with 1 ml of heat denatured probe per slide was added and incubated overnight in a humidi®ed chamber at 508C. The slides were washed with 26SSC for 30 min at room temperature, with 26SSC/ 50% formamide at 508C and with 16SSC at room temperature for 5 min, respectively. The immunological detection was performed using an anti-digoxigenin-alkaline phosphatase conjugate.
For immunostaining, deparanized sections of formalin®xed tissues were microwaved (5 min), incubated for 15 min in 10 mM citrate buer (pH 6) at 908C, treated with 0.3% hydrogen peroxide (30 min) and incubated overnight at 48C with the primary antibodies (goat polyclonal PTN IgG N-15 at 1 : 150, Santa Cruz Biotechnology, Santa Cruz, CA, USA; mouse monoclonal anti-cytokeratin AE3 at 1 : 200, Boehringer Mannheim). After 30 min incubation with the respective biotinylated secondary antibody (at 1 : 500, Vector Laboratories, Burlingame, CA, USA) and 1 h treatment with the ABC peroxidase system (Vectastain Elite ABC kit; Vector Laboratories) the slides were incubated in chromogen diaminobenzidine tetrahydrochloride (*4 min) and counterstained with hematoxylin.
Generation of promoter-reporter constructs
Various regions from the 1.9 kb HindIII-BamHI (H,B) promoter fragment of the human PTN gene were cloned into the promoterless ®re¯y luciferasereporter vectors pXP-1 or pXP-2 (Nordeen, 1988) . Based on the transcription start site of the HERV-PTN fusion transcript , the 1.9 kb H,B fragment corresponds to position 71266 to +631 of the HERVderived promoter of the human PTN gene and is named construct 71266/+631.
Construct 7729/+631 was made via NcoI/SmaI double digestion of construct 71266/+631, followed by a ®ll-in reaction and religation. The constructs 7601/+631 and 7353/+631 were generated by PCR using sense HindIIIlinker primers (5'-GGTAAGCTTGATAGAGAGAAGCAA-CATG-3' (7601 to 7583); 5'-GGTAAGCTTCAGAAAGT-TAGATACCATG-3' (7353 to 7335)) in combination with an antisense primer (5'-CCATCCTCTAGAGGATA-GAATGGCGCCGGGCC-3') complementary to the ®re¯y luciferase cDNA sequence (LUC32; position 110 to 79 (DeWet et al., 1987) ). After ligation into the pCR2.1 vector (Invitrogen, Pontiac, CA, USA), each fragment (7601/+631 and 7353/+631) was inserted via HindIII digestion in the pXP-2 vector. Construct 71266/+404 was generated by deletion of the region +404 to +631 in construct 71266/ +631 via SacI digestion and religation. To generate construct 7601/+32, a PCR reaction with a sense HindIII-linker primer (5'-GGTAAGCTTGATAGAGAGAAGCAACATG-3', 7601 to 7583) and an antisense primer (5'-GA-GAGGGTCTCTCTTGTC-3', +32 to +15) was performed using construct 71266/+631 as the template. After cloning into the pCR2.1 vector (Invitrogen) region 7601/+32 was inserted via HindIII digestion into pXP-1. Construct +404/ +631 was made by SacI digestion of construct 71266/+631, gel puri®cation and cloning into pXP-1. Construct +404/ +486 was made via SacII/SmaI double digestion of +404/ +631 and religation; construct +486/+404 via SacII/XhoI digestion of construct +631/+404 and religation; construct +444/+486 via PvuII/BamHI and construct +404/+444 via PvuII/HindIII digestion of construct +404/+486 followed by religation.
To mutate the exon UV3 splice donor (SD) at two positions via PCR, two mutagenesis primers (5'-CAT-TACTCGTCTCGCTTGCCGGTCAGGG-3', antisense, +542 to +515; 5'-GCAAGCGAGACGAGTAATG-GACGGTCCAGG-3', sense, +524 to +553) were used in combination with sense primer A (5'-CCTGACTTGCTC AGTCGATC-3', +316 to +335), antisense primer B (5'-CCATCCTCTAGAGGATAGAATGGCGCCGGGCC-3', LUC32; luciferase cDNA position 110 to 79 (DeWet et al., 1987) ) and construct 71266/+631 as a template, respectively. After puri®cation via gel®ltration (CLONTECH, Palo Alto, CA, USA), both PCR products were combined at a 1 : 1 ratio and primers A and B were added after the 5th cycle of the second PCR. The PCR product was cloned via SacI into the pXP-1 vector to generate the constructs +404/+631 SDmt and +631/+404 SDmt.
To analyse the activity of various promoter regions upstream of a heterologous promoter, the cytomegalovirus minimal promoter region 753 to +75 (CMVmi) was cloned into the pXP-1 vector. In detail, the 157 nt long CMVmi promoter fragment (753/+75) was isolated from the modi®ed pUHC13-3 plasmid by SmaI digestion and ligated into the pXP-1 vector. Construct +404/+468-CMVmi was made by SalI digestion of construct +404/+486 and insertion of the SmaI 157 nt CMVmi promoter fragment after a ®ll-in reaction. Construct +486/+404-CMVmi was made via insertion of the CMVmi SmaI fragment into construct +486/+404. Construct +443/+486-CMVmi was made via PvuII/BamHI double digestion of construct +404/+486-CMVmi and religation, construct +443/+404-CMVmi via PvuII/BamHI double digestion of construct +486/+404-CMVmi followed by religation.
To reveal the role of the Sp1 binding site at position +451 to +462 on the transcriptional activity of construct +443/ +486-CMVmi, a mutant +443/+490 fragment was cloned upstream of the CMVmi promoter. For this purpose, BamHI-linker sense and XhoI-linker antisense oligonucleotides from region +443 to +490 containing the mutation were mixed at equal molarity, denaturated at 958C for 5 min in 10 mM Tris-HCl pH 7.5/20 mM NaCl, incubated in a 758C preheated waterbath and allowed to cool down to room temperature for 12 h and cloned in BamHI/XhoI doubledigested construct CMVmi (+443/+490mtSP1; C to A transversions at position +459 and +460, sense 5'-GAT-CGCTGATTAAAGCCACTAACTTCACTATCTCGGTG-TCTCCTGTCCGCGGC-3', antisense 5'-TCGAGCCGCG-GACAGGAGACACCGAGATAGTGAAGTTAGTGGCT-TTAATCAGCG-3').
To study the role of the Sp1 binding site at position +451 to +462 on the transcriptional activity of the promoter, the binding site was mutated via PCR. Mutagenesis antisense (5'-GATAGTGAAGTTAGTGGCTTTAATCAGCTGG-3', +470 to +440) and sense (5'-AAGCCACTAACTTCACTATCTC-GGTGTCTC-3', +451 to +481) primers were used in combination with sense primer A (5'-CCTGACTTGCT-CAGTCGATC-3', +316 to +335), antisense primer T7 (5'-TAATACGACTCACTATAGGG-3') and pCR2.1 clone 7601/+631 as the template. The procedure was done as outlined above generating the construct 7601/+631mt.Sp1.
Nuclear extracts and electrophoretic mobility shift assays (EMSAs)
Nuclear extracts were prepared as described elsewhere (Dignam et al., 1983) with modi®cations of Peter Johnson (personal communication) using 15 cm dishes with 50 to 80% con¯uent growing cells. After washing twice on ice with ice cold 16PBS, the cells were harvested by scraping, sedimented at 48C for 5 min with 500 g, resuspended in 1 ml ice cold buer A (in mM): KCl 15, HEPES 10 pH 7.6, MgCl 2 , EDTA 0.1, DTT 1, 0.1% Nonidet P-40, 16 protease inhibitor cocktail (Complete TM , Boehringer Mannheim), 1 mM sodium orthovanadate and lysed for 10 min on ice. The nuclei were sedimented at 48C for 5 min with 1000 g, resuspended in 50 ml MgCl 2 -free buer B (0.42 M NaCl, 20 mM HEPES pH 7.9, 25% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 16protease inhibitor cocktail, 1 mM sodium orthovanadate) vortexed for 15 min at step 6 at 48C and sedimented for 10 min with 11 000 g. The protein content was de®ned with the Bio-Rad detection system (Hercules, CA, USA) and the extracts were stored at 7808C.
For the EMSAs, 10 ml binding reactions, containing 10 mM Tris-HCl pH 7.5, 10 mM KCl, 5% Glycerol, 0.1 mM DTT, 0.1 mM EDTA, 6 mg nuclear extracts from JEG-3 or HeLa cells or 5.5 mg whole cell extract from SL2 cells, 20 fmol double-stranded oligonucleotide probe (Figure 4a ) and 1 mg poly(dA:dT) (Pharmacia), were incubated for 45 min on ice. Double-stranded oligonucleotides were generated from complementary single stranded oligonucleotides as described above. Endlabeling of the probes was performed with T4 Polynucleotide Kinase and 50 mCi g 32 P-ATP (6000 Ci/mmol) followed by Sephadex G-25 gel®ltration chromatography (Boehringer Mannheim). Oligonucleotide competitors were added at dierent molar excess to the binding reactions as indicated in the respective sections. The protein-DNA complexes were separated on a 6% native TBE polyacrylamide gel (29 : 1, acrylamide:bisacrylamide; 50 mM Tris, 50 mM boric acid, 1 mM EDTA) with 80 V at room temperature. For the supershift experiment, the extract was preincubated with 1 ml anti-Sp1 antibody or with equal volume unrelated IgG for 10 min on ice prior to the addition of the probe. After further 45 min incubation on ice, the complexes were resolved on a 4% polyacrylamide gel as mentioned above.
